Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).
Atomo Diagnostics Limited announced it will release its Q1 FY26 results on October 29, 2025, followed by a webinar hosted by Managing Director & CEO, John Kelly. This announcement highlights Atomo’s ongoing commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations positively.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that provides unique, integrated rapid diagnostic test devices to the global diagnostic market. The company’s patented devices are designed to simplify testing procedures, enhance usability, and improve reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized products internationally and has supply agreements for tests targeting infectious diseases such as COVID-19, HIV, viral versus bacterial differentiation, and female health.
Average Trading Volume: 1,799,245
Technical Sentiment Signal: Buy
Current Market Cap: A$21.87M
See more data about AT1 stock on TipRanks’ Stock Analysis page.